Abbott announced the US Food and Drug Administration (FDA) has approved the company's Proclaim XR recharge-free neurostimulation system for people living with chronic pain. The Proclaim XR platform ...

(RTTNews) - Abbott Laboratories, Inc. (ABT) announced Thursday that the U.S. Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful ...

The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more effective ...

It was originally approved in 2019 for the treatment of chronic pain. The Food and Drug Administration (FDA) has approved the Proclaim™ XR spinal cord stimulation (SCS) system for the treatment of ...

The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more effective ...

Abbott, a global healthcare leader, announced that the US Food and Drug Administration (FDA) has approved new expanded magnetic resonance imaging (MRI) compatibility for its Proclaim XR Spinal Cord ...

The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more effective ...

NORTH CHICAGO (dpa-AFX) - Abbott Laboratories, Inc. (ABT) announced Thursday that the U.S. Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat ...